Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-07-19

Clinical Trial Update: Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial evaluating safety and preliminary efficacy of 177Lu-OPS201 in neuroendocrine tumors was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • 177Lu-OPS201 (Lu-177 OPS201)

Snippet

Sponsor: Ipsen | Conditions: Neuroendocrine Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-07-19